News Daily News Tricky Population of Patients With A-fib Undergoing PCI Tackled in New Consensus Document Todd Neale November 29, 2016
News Industry News Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan November 29, 2016
News Conference News AHA 2016 My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial Shelley Wood November 28, 2016
News Daily News Anemia Common in ACS Patients, Linked with Higher Mortality Michael O'Riordan November 23, 2016
News Conference News AHA 2016 Stress Testing May Be Increasing Among Younger Patients With Commercial Health Insurance L.A. McKeown November 23, 2016
News Conference News AHA 2016 La Pruebas de Esfuerzo podrían estar Aumentando en Pacientes Más Jóvenes con Seguro Médico Comercial L.A. McKeown November 23, 2016
News Daily News Beta-blocker Therapy Seems to Boost Post-PCI Outcomes in Patients With ACS Todd Neale November 22, 2016
News Conference News AHA 2016 Chest Pain Clinic Reduces Emergency Department and Hospital ‘Frequent Fliers’ Michael O'Riordan November 21, 2016
News Conference News AHA 2016 Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women L.A. McKeown November 17, 2016
News Conference News AHA 2016 Proton Pump Inhibitor Use Tied to Elevated Ischemic Stroke Risk Todd Neale November 16, 2016
News Conference News AHA 2016 Según Datos a Nivel Nacional, las PCI realizadas en Centros Sin Soporte Quirúrgico ‘Probablemente No Tengan Problemas’ Yael L. Maxwell November 16, 2016
News Conference News AHA 2016 PCI at Centers Without Surgical Backup ‘Probably OK,’ Nationwide Data Suggests Yael L. Maxwell November 16, 2016
Presentation AHA 2016 PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Presenter: Michael Gibson November 15, 2016
Presentation AHA 2016 Arterial Revascularization Trial (ART) Presenter: David P. Taggart November 15, 2016
Presentation AHA 2016 The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I) Presenter: Michael Gibson November 15, 2016
Presentation AHA 2016 FUnctional Testing Underlying REvascularization: The FUTURE trial Presenter: Gilles Rioufol November 15, 2016
News Conference News AHA 2016 Incomplete Revascularization Linked With Increased MACE in Subsequent Noncardiac Surgery Michael O'Riordan November 15, 2016